Invivyd (NASDAQ:IVVD) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report issued on Thursday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

A number of other research analysts also recently commented on IVVD. Morgan Stanley dropped their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a report on Monday, February 24th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Invivyd presently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.74 on Thursday. The stock’s 50-day moving average is $0.98 and its two-hundred day moving average is $0.87. Invivyd has a 1-year low of $0.35 and a 1-year high of $4.74. The company has a market cap of $88.28 million, a price-to-earnings ratio of -0.38 and a beta of 0.09.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10. The company had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $13.57 million. Equities research analysts anticipate that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Terrance Mcguire sold 83,817 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the completion of the sale, the director now directly owns 3,340,520 shares of the company’s stock, valued at $1,803,880.80. This represents a 2.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 246,138 shares of company stock worth $120,902. 17.90% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

A number of large investors have recently made changes to their positions in the company. Barclays PLC boosted its position in shares of Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after purchasing an additional 9,207 shares during the period. State Street Corp boosted its position in shares of Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the period. Jane Street Group LLC lifted its position in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after acquiring an additional 87,358 shares during the period. Renaissance Technologies LLC acquired a new stake in Invivyd during the 4th quarter worth approximately $74,000. Finally, Two Sigma Investments LP lifted its position in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.